Line 29: | Line 29: | ||
<li><a href="https://2017.igem.org/Team:Kyoto/Project_Details">Proof of concept</li> | <li><a href="https://2017.igem.org/Team:Kyoto/Project_Details">Proof of concept</li> | ||
</ul> | </ul> | ||
− | </li><li><a href="https://2017.igem.org/Team:Kyoto/Experiments">Material&Methods</a></li><li><a href="https://2017.igem.org/Team:Kyoto/Achievements">Achievements</a></li><li><a href="https://2017.igem.org/Team:Kyoto/Notebook">Notebook</a></li><li><a href="https://2017.igem.org/Team:Kyoto/Practice">Practice</a> | + | </li><li><a href="https://2017.igem.org/Team:Kyoto/Experiments">Material&Methods</a></li><li><a href="https://2017.igem.org/Team:Kyoto/Achievements">Achievements</a> |
+ | <ul> | ||
+ | <li><a href="https://2017.igem.org/Team:Kyoto/HP/Silver">HP/Silver</a></li></ul></li><li><a href="https://2017.igem.org/Team:Kyoto/Notebook">Notebook</a></li><li><a href="https://2017.igem.org/Team:Kyoto/Practice">Practice</a> | ||
<ul> | <ul> | ||
<li><a href="https://2017.igem.org/Team:Kyoto/integrated">Human Practice</a></li> | <li><a href="https://2017.igem.org/Team:Kyoto/integrated">Human Practice</a></li> | ||
− | <li><a href="https://2017.igem.org/Team:Kyoto/ | + | <li><a href="https://2017.igem.org/Team:Kyoto/Collaborations">Collaboration</li> |
− | </ul></li><li><a href="https://2017.igem.org/Team:Kyoto/Team">Team</a></li><li><a href="https://2017.igem.org/Team:Kyoto/Safety">Safety</a></li> | + | </ul></li><li><a href="https://2017.igem.org/Team:Kyoto/Team">Team</a> |
+ | <ul> | ||
+ | <li><a href="https://2017.igem.org/Team:Kyoto/Team">Members</li> | ||
+ | <li><a href="https://2017.igem.org/Team:Kyoto/Attributions">Attributions</li> | ||
+ | </ul></li><li><a href="https://2017.igem.org/Team:Kyoto/Safety">Safety</a></li> | ||
</ul> | </ul> | ||
</header> | </header> |
Revision as of 14:30, 18 October 2017
Material&Methods
- 1.Parts
- 2.Primer list
- 3.Materials
- 3-1. Kit
- 3-2. Restricton Enzyme
- 3-3. Polymerase
- 3-4. DNA ligase
- 3-5. Marker
- 3-6. Organism
- 3-7. Antibiotics
- 3-8. Equipment
- 3-9. Backborns
- 3-10. Buffer
- 3-11. SDSPAGE/Western blotting
- 4.Methods
- 4-1. Miniprep
- 4-2. Gel Extraction
- 4-3. Restrict Enzyme Digestion
- 4-4. Ligation
- 4-5. Transformation
- 4-6. PCR
- 4-7. Sequencing
- 4-8. RT-PCR
- 4-10. Western blotting(Membrane fraction)
1.Parts
2.Primer list
Primer name | Sequence | Length | Tm | GC% | Designer | Manufacturer |
---|
3.Materials
Name | Supplier |
---|---|
Name | Supplier |
---|---|
Name | Supplier |
---|---|
Name | Supplier |
---|---|
Name | Supplier |
---|---|
Name | Supplier |
---|---|
Name | Supplier |
---|---|
Name | Supplier |
---|---|
Name | Supplier |
---|---|
Name | Supplier |
---|---|
Name | Supplier |
---|---|